Advertisement

Inflammopharmacology

, Volume 15, Issue 1, pp 5–9 | Cite as

Pharmacological profile of ramosetron, a novel therapeutic agent for IBS

  • T. HirataEmail author
  • T. Funatsu
  • Y. Keto
  • M. Nakata
  • M. Sasamata
Review

Abstract.

Ramosetron is a potent and selective serotonin (5-HT)3 receptor antagonist that has been shown to affect abnormal colonic function and abdominal pain in animals. Ramosetron (0.3 to 100 µg/kg, p.o.) has been found to significantly suppress abnormal defecation induced by conditioned-fear stress (CFS), restraint stress, corticotropin releasing factor (CRF) and 5-HT in rats and mice, and these effects were more potent than those of alosetron, cilansetron or loperamide. On the other hand, ramosetron (3,000 µg/kg, p. o., once daily for 7 days) did not inhibit normal defecation in dogs while tiquizium significantly inhibited it. Ramosetron (3 to 100 µg/kg, p. o.) also significantly prevented CFS-induced acceleration of colonic transit and CRF-induced abnormal water transport in rats, respectively. Moreover, ramosetron (0.3 to 3 µg/kg, p. o.) significantly suppressed restraint stress-induced decrease in colonic pain threshold, an effect not observed with loperamide. These results indicate that ramosetron produce beneficial clinical effects on IBS symptoms.

Keywords.

Ramosetron 5-HT3 receptor IBS Defecation Diarrhea Colonic transit Water transport Abdominal pain 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Birkhäuser Verlag, Basel 2007

Authors and Affiliations

  • T. Hirata
    • 1
    Email author
  • T. Funatsu
    • 1
  • Y. Keto
    • 1
  • M. Nakata
    • 1
  • M. Sasamata
    • 1
  1. 1.Pharmacology Research Laboratories, Drug Discovery ResearchAstellas Pharma IncIbarakiJapan

Personalised recommendations